Novavax: Covid-19 Vaccine Opportunity Still at Play
25/2 08:59
With Russia’s attack on Ukraine at the forefront of the current news flow, Covid has been put on the backburner for now.
That said, as has been proven before with the emergence of new variants, it is still too early to say with certainty the pandemic is finally behind us. In any case, over the long run, in similar fashion to the flu, annual boosters to protect against Covid will be required.
So, there is still room for Covid-19 vaccine makers to make their mark, which bodes well for one of the leading coronavirus stocks – Novavax (NVAX), as noted by Jefferies’ Roger Song.
“NVAX’s CV19 vaccine has high efficacy/immunogenicity and clean safety/ tolerability, as well as convenient logistics and well-validated protein-based technology,” the analyst said. “As a result, we believe it could play a meaningful role in the future CV19 vaccine market.”
That “impressive” clinical profile of NVX-CoV2373 stands up well against the two leading mRNA-based vaccines. Technical advantages, like the undemanding shipping/storage requirements are a plus and so is the “well-validated/common” technology, which could be a...